Pertento Partners LLP Acquires Shares of 270,421 Nutex Health Inc. $NUTX

Pertento Partners LLP bought a new position in Nutex Health Inc. (NASDAQ:NUTX) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 270,421 shares of the company’s stock, valued at approximately $27,940,000. Nutex Health makes up approximately 3.2% of Pertento Partners LLP’s investment portfolio, making the stock its 13th largest position.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Topline Capital Management LLC raised its holdings in Nutex Health by 72.0% during the 2nd quarter. Topline Capital Management LLC now owns 309,131 shares of the company’s stock valued at $38,484,000 after acquiring an additional 129,418 shares during the period. Marshall Wace LLP grew its holdings in Nutex Health by 333.4% during the 2nd quarter. Marshall Wace LLP now owns 94,548 shares of the company’s stock valued at $11,770,000 after buying an additional 72,734 shares in the last quarter. Divisadero Street Capital Management LP bought a new stake in shares of Nutex Health during the second quarter valued at about $7,481,000. Geode Capital Management LLC increased its position in shares of Nutex Health by 116.8% during the second quarter. Geode Capital Management LLC now owns 78,859 shares of the company’s stock valued at $9,819,000 after buying an additional 42,484 shares during the period. Finally, Pacer Advisors Inc. bought a new stake in shares of Nutex Health during the third quarter valued at about $3,299,000. 5.32% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently commented on NUTX. Weiss Ratings restated a “hold (c)” rating on shares of Nutex Health in a research report on Monday, December 29th. Wall Street Zen lowered shares of Nutex Health from a “strong-buy” rating to a “hold” rating in a report on Saturday, March 7th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $252.50.

Nutex Health Price Performance

Shares of NASDAQ NUTX opened at $90.49 on Thursday. Nutex Health Inc. has a twelve month low of $43.81 and a twelve month high of $193.07. The company has a quick ratio of 3.39, a current ratio of 3.41 and a debt-to-equity ratio of 0.70. The firm has a market capitalization of $630.72 million, a P/E ratio of 10.08 and a beta of 0.03. The stock’s 50-day simple moving average is $131.77 and its two-hundred day simple moving average is $124.74.

Nutex Health (NASDAQ:NUTX) last announced its earnings results on Thursday, March 5th. The company reported $1.61 earnings per share for the quarter, missing analysts’ consensus estimates of $5.56 by ($3.95). Nutex Health had a net margin of 7.34% and a return on equity of 17.67%. The company had revenue of $151.68 million during the quarter, compared to analysts’ expectations of $258.82 million.

About Nutex Health

Nutex Health, Inc (NASDAQ: NUTX) is an integrated outpatient healthcare services company based in San Antonio, Texas. The company focuses on delivering a range of ambulatory care solutions, including urgent care, telemedicine, medical imaging, teleradiology, weight‐loss services and behavioral health support. By combining in‐person clinics with virtual care capabilities, Nutex Health aims to provide patients with accessible, cost‐effective treatment options outside traditional hospital settings.

The company’s urgent care network operates through both standalone and retail‐anchored centers, offering treatment for non‐life‐threatening injuries and illnesses, preventive screenings and basic primary care.